NCT01455090 is a Phase 2 clinical trial of BMS-650032 in Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT01455090?

NCT01455090 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT01455090?

Interventions in NCT01455090: BMS-650032, BMS-790052, BMS-791325, Ribavirin.

What condition does NCT01455090 study?

NCT01455090 studies Chronic Hepatitis C.

Is NCT01455090 still recruiting?

NCT01455090 is currently completed. Last updated 27 April 2017.

Last reviewed 2017-04-27 · How we verify

NCT01455090

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Completed Phase 2 Last updated 27 April 2017

What this trial tests

Phase 2 trial testing BMS-650032 in Chronic Hepatitis C in 320 participants. Completed in 31 July 2015.

Timeline

30 November 2011

Primary endpoint
31 March 2014

31 July 2015

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	320
Start date	30 November 2011
Primary completion	31 March 2014
Estimated completion	31 July 2015
Sites	32 locations across France, Puerto Rico, United States

Drugs / interventions tested

BMS-650032 — full drug profile →
BMS-790052 — full drug profile →
BMS-791325 — full drug profile →
Ribavirin — full drug profile →

Conditions studied

Chronic Hepatitis C — all drugs for Chronic Hepatitis C →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Chronic Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA \< LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment naive patients, and Genotype (GT1) infected patients who are prior null responders to pegIFN/ribavirin

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, et al · · 2014 · cited 147× · PMID 24184132 · DOI 10.1053/j.gastro.2013.10.057
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
Yau AH, Yoshida EM. · · 2014 · cited 51× · PMID 25229466 · DOI 10.1155/2014/549624
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA, Liu M, Gentles RG, Ding M, et al · · 2014 · cited 43× · PMID 24733465 · DOI 10.1128/aac.02495-13
Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
Wu S, Kanda T, Nakamoto S, Imazeki F, et al · · 2013 · cited 30× · PMID 24379619 · DOI 10.3748/wjg.v19.i47.8940
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
Sims KD, Lemm J, Eley T, Liu M, et al · · 2014 · cited 25× · PMID 24733462 · DOI 10.1128/aac.02579-13
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
Zhou N, Hernandez D, Ueland J, Yang X, et al · · 2016 · cited 24× · PMID 26170396 · DOI 10.1093/infdis/jiv379

Verify or expand the search:

Other recruiting trials for Chronic Hepatitis C

Currently open trials in the same condition.

NCT06180590 — The Efficacy of Vosevi in Treating DAA-experienced Patients · recruiting
NCT03993925 — Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01455090 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 27 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01455090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing